Asset

ATOMOXETINE

Apnimed Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06566820phase3enrolling_by_invitation2024-07-032026-06-30ApnimedContinuation Protocol for Obstructive Sleep Apnea (OSA)
NCT04905979phase2completed2021-07-312023-01-31ApnimedTrial of AD113 and Atomoxetine in OSA Patients With Hypertension

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)